EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
BMJ – May 04, 2024
Source: OpenAlex
Summary
The promising outlook for Psilocybin in treating Depression is undergoing critical re-evaluation. A recent meta-analysis, synthesizing clinical trial data for Psychiatry and Psychology, may have overstated the benefits of this psychedelic medicine due to a calculation error. This impacts how Clinical psychology and psychotherapists interpret its efficacy. The original authors are addressing the issue, which could significantly influence the field of Psychedelics and Drug Studies, future Digital Mental Health Interventions, and broader Psychotherapy Techniques in Medicine. The BMJ will review their response to ensure robust conclusions.
Abstract
The journal and the authors are investigating the problem.The study analysed data from randomised trials of psilocybin for the treatment of depression in adults.A methodological concern has been raised about an error in the calculation of standardised mean differences.This is likely to have overestimated the benefits of psilocybin.The authors are reviewing and responding to the error and its implications for the findings and conclusions of the paper.The authors' response will be reviewed by The BMJ who will decide what further action is needed.